Bicara plans Q3 alternative dosing study of ~150–200 patients as it targets mid-2027 interim analysis
Bicara Therapeutics Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $20.62
-11% in 7d after detection
Post-detection moves
1h
—
1d
-2.4%
3d
-9.9%
7d
-11%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS